BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced today data from two studies of the company's ELAD(R) (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which was held November 2-6 in Boston, Mass.
-- Abstract (#91), "Interim results of Randomized Controlled Trial of
ELAD(R) in Acute on Chronic Liver Disease," was presented in a
parallel session on Monday, November 5th. This controlled, randomized
(2:1) clinical trial enrolled 69 patients with acute-on-chronic liver
failure in two protocols at two centers in Beijing, China. The first
49 patient protocol resulted in a 30 day transplant-free survival rate
of 50% in the controls and 87% in the treated group (p<0.01). The
second protocol, which had a shorter ELAD(R) treatment time, did not
reach statistical significance. Initial conclusions from this trial
demonstrated ELAD(R) is safe and effective in this patient population
when used with the longer treatment time.
-- Abstract (#855), "ELAD(R) Cellular and System Performance
Improvements," was a poster presentation detailing the metabolic
characteristics of the ELAD(R) cartridges in order to optimize
Terry Winters, Ph.D., Chairman and CEO said, "These data are consistent with our previous research and experience. ELAD is helping patients and the technology continues to be refined for optimum benefit. These are positive developments as we apply for marketing approval in China and advance our U.S. clinical program."
To date, only liver transplantation has been shown to increase
survival. However, demand for liver transplantation far exceeds the supply
of donor livers, creating a need for an alternative, lifesaving therapy
such as ELAD(R). In China alone, an estimated 160 million
|SOURCE Vital Therapies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved